Compare Fastly Inc (FSLY) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastly Inc vs Illumina, Inc. — how do they compare? Fastly Inc trades at $29.51 (market cap $4.03B), while Illumina, Inc. trades at $278.09 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 9.9× Fastly Inc's market cap, and Fastly Inc is more actively traded (5,516,495 versus 3,169,503). Which is the better fit depends on your goals — on Pluang, investors hold Fastly Inc for 26 Days and Illumina, Inc. for 83 Days on average.
| FSLY | ILMN | |
|---|---|---|
Market Cap | $4.03B | $39.95B |
Volume | 5,516,495 | 3,169,503 |
Sector | Technology | Health |
52-Week High | $33.50 | $293.69 |
52-Week Low | $7.86 | $91.00 |
Typical Hold Time | 26 Days | 83 Days |
Enterprise Value | $4.09B | $41.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastly (FSLY) trades at $29.3, up 15.9% on the day, with a neutral technical signal and bullish moving averages. The company reported three consecutive quarterly EPS beats, with Q3 2026 expected at $0.1186. Revenue growth is strong, reaching $624M in 2025, but net losses persist, though margins are improving. Recent news highlights AI-driven demand and insider selling by the CTO, creating mixed sentiment.
The outlook is cautiously optimistic, with revenue projected to hit $687M in 2026 and a path to profitability. Risks include sustained losses, competitive pressure, and high valuation multiples. Analyst consensus is mixed, with a $28.25 price target slightly below current levels, suggesting limited near-term upside amid growth execution risks.
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
